Company profile
Vivacelle Bio, Inc.
A New Paradigm In Fluid Resuscitation
- Industry
- Biotechnology Research
- Employees
- 17
- Headquarters
- Chicago, Illinois
- Founded
- 2013
- LinkedIn followers
- 552
- Office locations
- 2
Vivacelle Bio, Inc. company summary
Vivacelle Bio, Inc. is a company in the Biotechnology Research industry, headquartered in Chicago, Illinois, founded in 2013. On LinkedIn the company has around 17 employees and 552 followers. The company lists 2 office locations. Its listed specialties include Bionanotechnology, Micelles, Treatment for hypovolemia, Biotechnology.
What technology does Vivacelle Bio, Inc. use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Vivacelle Bio, Inc.
VIVACELLE BIO, Inc. is a developmental stage biotechnology company developing products utilizing nanoparticle technology. Their first product, VBI-1, a colloid non-blood volume expander appears to be safer and far more effective than the standard treatment for hypovolemia in animal studies and received green light from FDA to start a phase IIa clinical trial in hypovolemia due to blood loss. The immediate other product in the pipeline is VBI-S, targeting hypovolemia due to sepsis/septic shock. Hypovolemia results from inadequate fluid volume in the blood vessels, causes the death of over a one million people globally each year. Major causes for fluid loss are trauma, surgery, shock, sepsis, severe diarrhea and burns. Inadequate circulating volume impairs tissue perfusion and oxygenation leading to cell injury and death. Rapid volume replacement and re-establishment of normal blood pressure are essential for survival. Currently available options of fluid replacements are non-blood volume expanders (colloids and crystalloids), blood products and blood substitutes. They have proven to be impractical and have the potential for significant negative adverse effects. VBI-1, represents a new paradigm in fluid resuscitation, safely restoring blood vessel volume and reversing the effects of hypovolemia. VBI-1 also modulates Nitric Oxide (a potent vasodilator that drops the blood pressure and a precursor to highly highly toxic mediators), reduces reperfusion injury, inhibits the inflammatory response, clears the endotoxin, metabolizes to naturally-occurring components and acts as an energy source. In addition, it can be loaded with readily available oxygen.
Specialties
Where is Vivacelle Bio, Inc. located?
Vivacelle Bio, Inc. lists 2 office locations.
Compare companies similar to Vivacelle Bio, Inc.
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Vivacelle Bio, Inc. vivacellebio.com | Biotechnology Research | 17 | 2013 | Chicago, Illinois |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Vivacelle Bio, Inc.
What does Vivacelle Bio, Inc. do?
VIVACELLE BIO, Inc. is a developmental stage biotechnology company developing products utilizing nanoparticle technology. Their first product, VBI-1, a colloid non-blood volume expander appears to be safer and far more effective than the standard treatment for hypovolemia in animal studies and received green light from FDA to start a phase IIa clinical trial in hypovolemia due to blood loss. The immediate other product in the pipeline is VBI-S, targeting hypovolemia due to sepsis/septic shock. Hypovolemia results from inadequate fluid volume in the blood vessels, causes the death of over a one million people globally each year. Major causes for fluid loss are trauma, surgery, shock, sepsis, severe diarrhea and burns. Inadequate circulating volume impairs tissue perfusion and oxygenation leading to cell injury and death. Rapid volume replacement and re-establishment of normal blood pressure are essential for survival. Currently available options of fluid replacements are non-blood volume expanders (colloids and crystalloids), blood products and blood substitutes. They have proven to be impractical and have the potential for significant negative adverse effects. VBI-1, represents a new paradigm in fluid resuscitation, safely restoring blood vessel volume and reversing the effects of hypovolemia. VBI-1 also modulates Nitric Oxide (a potent vasodilator that drops the blood pressure and a precursor to highly highly toxic mediators), reduces reperfusion injury, inhibits the inflammatory response, clears the endotoxin, metabolizes to naturally-occurring components and acts as an energy source. In addition, it can be loaded with readily available oxygen.
How many employees does Vivacelle Bio, Inc. have?
Vivacelle Bio, Inc. has around 17 employees on LinkedIn.
Where is Vivacelle Bio, Inc. headquartered?
Vivacelle Bio, Inc. is headquartered in Chicago, Illinois.
Where does Vivacelle Bio, Inc. have offices?
Vivacelle Bio, Inc. lists 2 office locations, including Chicago, Illinois, US; Fort Wayne, IN, US.
When was Vivacelle Bio, Inc. founded?
Vivacelle Bio, Inc. was founded in 2013.
Build a lead list from companies like Vivacelle Bio, Inc.
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.